Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity BLS Pharmaceuticals Limited ABN/ARBN Financial year ended: 97 084 464 193 30 June...
Appendix 4G Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
BLS Pharmaceuticals Limited on 6ix
In the deck
Earlier from BLS Pharmaceuticals
- BLS FY2027 Guidance
- BLS Investor Presentation
- BLS FY2026 Results Announcement
- Annual Report to shareholders
- BLS FY2026 Results Webinar 2 September 2026 8am AEST
Later from BLS Pharmaceuticals
- Application for quotation of securities - BLS
- S&P DJI Announces September 2026 Quarterly Rebalance
- Angus Walker Appointed Alternate Director to Edward Myer
- Initial Director's Interest Notice
- AGM Date and Director Nominations
Follow BLS Pharmaceuticals into a list and get an email when it puts out news.
Follow BLS Pharmaceuticals